Development of Antibodies and Chimeric Molecules for Cancer Immunotherapy

Advances in Immunology

Volumn 90, Issue , 2006, Pages 83-131

  Waldmann, Thomas A ^a   Morris, John C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; ANTHRACYCLINE; BASILIXIMAB; BEVACIZUMAB; CD20 ANTIBODY; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACLIZUMAB; DENILEUKIN DIFTITOX; DOXORUBICIN; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; INFLIXIMAB; MONOCLONAL ANTIBODY; PACLITAXEL; PHENYLALANINE; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNINDEXED DRUG; VALINE; VASCULOTROPIN ANTIBODY; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; APOPTOSIS; BREAST CANCER; BRONCHOSPASM; CANCER; CANCER IMMUNOTHERAPY; CHILL; CLINICAL TRIAL; COLORECTAL CANCER; CYTOTOXICITY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG APPROVAL; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SYNTHESIS; DRUG TARGETING; FEVER; FOOD AND DRUG ADMINISTRATION; GENETIC ENGINEERING; HEART INFARCTION; HUMAN; HYPOTENSION; IMMUNOCOMPETENT CELL; INJECTION SITE REACTION; LUNG EMBOLISM; LUNG HEMORRHAGE; LYMPHATIC LEUKEMIA; MUCOSAL BLEEDING; NAUSEA; NEPHROSIS; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RASH; REVIEW; THROMBOEMBOLISM; VOMITING;

ANIMALS; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; GENE TARGETING; HUMANS; IMMUNIZATION, PASSIVE; NEOPLASMS; PROTEIN ENGINEERING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT FUSION PROTEINS;

EID: 33646793312     PISSN: 00652776     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2776(06)90003-0     Document Type: Review

References (194)

1. Adams G.P., Schier R., McCall A.M., et al. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br. J. Cancer 77 (1998) 1405-1412
2. Adams G.P., and Weiner L.M. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23 (2005) 1147-1157
3. Amadori S., Suciu S., Willemze R., et al. Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: A phase II study (AML-15) of the EORTC and GIMEMA leukemia groups. Haematologica 89 (2004) 950-956
4. Axworthy D.B., Reno J.M., Hylarides M.D., et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc. Natl. Acad. Sci. USA 97 (2000) 1802-1807
5. Bagshawe K.D. Antibody-directed enzyme prodrug therapy for cancer: Its theoretical basis and application. Mol. Med. Today 1 (1995) 424-431
6. ™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58 (1998) 2825-2831
7. Baselga J., Tripathy D., Mendelsohn J., et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14 (1996) 737-744
8. Baselga J., Pfister D., Cooper M.R., et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. 18 (2000) 904-914
9. Bennett J.M., Kaminski M.S., Leonard J.P., et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood 105 (2005) 4576-4582
10. Berinstein N.L., Grillo-Lopez A.J., White C.A., et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. 9 (1998) 995-1001
11. Bielekova B., Richert N., Howard T., et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc. Natl. Acad. Sci. USA 101 (2004) 8705-8708
12. Bowen A.L., Zomas A., Emmett E., et al. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br. J. Haematol. 96 (1997) 617-619
13. Burke J.M., Caron P.C., Papadopoulos E.B., et al. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant. 32 (2003) 549-556
14. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer 1 (2001) 118-129
15. Carter P., and McDonagh C.F. Designer antibody-based therapeutics for oncology. 7th International Congress on monoclonal antibodies (2005), Physicians Education Publisher, Dallas, Texas 147-154
16. Carter P., Presta L., Gorman C.M., et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA 89 (1992) 4285-4289
17. Cartron G., Dacheux L., Salles G., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99 (2002) 754-758
18. Chester K., Pedley B., Tolner B., et al. Engineering antibodies for clinical applications in cancer. Tumor Biol. 25 (2004) 91-98
19. Chinn P.C., Leonard J.E., Rosenberg J., et al. Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. Int. J. Oncol. 15 (1999) 1017-1025
20. Clynes R.A., Towers T.L., Presta L.G., et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6 (2000) 443-446
21. Cobleigh M.A., Vogel C.L., Tripathy D., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17 (1999) 2639-2648
22. Coiffier B., Lepage E., Briere J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346 (2002) 235-242
23. Coles A.J., Wing M., Smith S., et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 354 (1999) 1691-1695
24. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351 (2004) 337-345
25. Davies A.J., Rohatiner A.Z., Howell S., et al. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 22 (2004) 1469-1479
26. Davis T.A., Grillo-Lopez A.J., White C.A., et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment. J. Clin. Oncol. 18 (2000) 3135-3143
27. Davis T.A., Kaminski M.S., Leonard J.P., et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin. Cancer Res. 10 (2004) 7792-7798
28. Denny W.A. Tumor-activated prodrugs-a new approach to cancer therapy. Cancer Invest. 22 (2004) 604-619
29. De Santes K., Slamon D., Anderson S.K., et al. Radiolabeled antibody targeting of the HER-2/neu oncoprotein. Cancer Res. 52 (1992) 1916-1923
30. Di Gaetano N., Cittera E., Nota R., et al. Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol. 171 (2003) 1581-1587
31. Dinndorf P.A., Andrews R.G., Benjamin D., et al. Expression of normal myeloid-associated antigens by acute leukemia cells. Blood 67 (1986) 1048-1053
32. Dong H., Strome S.E., Salomao D.R., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat. Med. 8 (2002) 793-800
33. Dowell J.A., Korth-Bradley J., Liu H., et al. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J. Clin. Pharmacol. 41 (2001) 1206-1214
34. Dowsett M., Bartlett J., Ellis I.O., et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J. Pathol. 199 (2003) 418-423
35. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 4 (2004) 11-22
36. Dranoff G. CTLA-4 blockade: Unveiling immune regulation. J. Clin. Oncol. 23 (2005) 662-664
37. Dupont J., Rothenberg M., Springs D., et al. Safety and pharmacokinetics of intravenous VEGF trap in a Phase I clinical trial of patients with advanced solid tumors. J. Clin. Oncol. 23 Suppl. 16S (2005) 3029
38. Ehrlich P. On immunity with special reference to cell life: Croonian lecture. In: Himmelweir B. (Ed). "The Collected Papers of Paul Ehrlich" Vol. II (1956), Immunology and Cancer Research, Pergammon, London 148-192 195-196
39. Essand M., Gronvik C., Hartman T., et al. Radioimmunotherapy of prostatic adenocarcinomas: Effects of 131I-labelled E4 antibodies on cells at different depth in DU 145 spheroids. Int. J. Cancer 63 (1995) 387-394
40. Fan Z., Masui H., Altas I., and Mendelsohn J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 53 (1993) 4322-4328
41. Flavell R.A., and Gorelik L. Transforming growth factor-B in T cell biology. Nat. Rev. Immunol. 2 (2002) 46-53
42. Freeman G.J., Long A.J., Iwai Y., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192 (2000) 1027-1034
43. Freeman S.D., Kelm S., Barber E.K., et al. Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood 85 (1995) 2005-2012
44. Gabrilovich D., Ishida T., Oyama T., et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92 (1998) 4150-4166
45. Gerber H.P., and Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 65 (2005) 671-680
46. Goldstein G. An overview of Orthoclone OKT3 transplantation proceedings. "Proceedings of an International Symposium on Monoclonal Antibody Therapy with Orthoclone OKT3 in Renal Transplantation.". Transplant. Proc. 18 (1986) 927-930
47. Goldstein N.I., Prewett M., Zuklys K., et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1 (1995) 1311-1318
48. Gordon M.S., Margolin K., Talpaz M., et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 19 (2001) 843-850
49. Gorelik L., and Flavell R.A. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat. Med. 7 (2001) 1118-1122
50. Grazette L.P., Boecker W., Matsui T., et al. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: Implications for herceptin-induced cardiomyopathy. J. Am. Coll. Cardiol. 44 (2004) 2231-2238
51. Gura T. Therapeutic antibodies: Magic bullets hit the target. Nature 417 (2002) 584-586
52. Hale G., Bright S., Chumbley G., et al. Removal of T cells from bone marrow for transplantation: A monoclonal antilymphocyte antibody that fixes human complement. Blood 62 (1983) 873-882
53. Hale G., Dyer M.J., Clark M.R., et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 2 (1988) 1394-1399
54. Hamann P.R., Hinman L.M., Hollander I., et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug. Chem. 13 (2002) 47-58
55. Herbst R.S., Arquette M., Shin D.M., et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J. Clin. Oncol. 23 (2005) 5578-5587
56. Herbst R.S., Kim E.S., and Harari P.M. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opin. Biol. Ther. 1 (2001) 719-732
57. Hericourt J., and Richet C. Physologie pathologique'-de la serotherapie dans la traitement du cancer. C.R. Hebd. Seanc. Acad. Sci. 121 (1895) 567
58. Hicklin D.J., and Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23 (2005) 1011-1027
59. Hinton P.R., Johlfs M.G., Xiong J.M., et al. Engineered human IgG antibodies with longer serum half-lives in primates. J. Biol. Chem. 279 (2004) 6213-6216
60. Hodi F.S., Mihm M.C., Soiffer R.J., et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. USA 100 (2003) 4712-4717
61. Hoeben A., Landuyt B., Highley M.S., et al. Vascular endothelial growth factor and angiogenesis. Pharmacol. Rev. 56 (2004) 549-580
62. Horning S.J., Younes A., Jain V., et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J. Clin. Oncol. 23 (2005) 712-719
63. Hudson P.J., and Souriau C. Engineered antibodies. Nat. Med. 9 (2003) 129-134
64. Hurwitz A.A., Foster B.A., Kwon E.D., et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 60 (2000) 2444-2448
65. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350 (2004) 2335-2342
66. Isaacs J.D., Watts R.A., Hazleman B.L., et al. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 340 (1992) 748-752
67. Iwai Y., Ishida M., Tanaka Y., et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. USA 99 (2002) 12293-12297
68. Izumi Y., Xu L., di Tomaso E., et al. Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature 416 (2002) 279-280
69. Jain R.K. Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev. 46 (2001) 149-168
70. Junghans R.P., and Anderson C.L. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc. Natl. Acad. Sci. USA 93 (1996) 5512-5516
71. Jurcic J.G., Larson S.M., Sgouros G., et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 100 (2002) 1233-1239
72. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21 (2003) 60-65
73. Kaminski M.S., Zasadny K.R., Francis I.R., et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J. Clin. Oncol. 14 (1996) 1974-1981
74. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N. Engl. J. Med. 352 (2005) 441-449
75. Keating M.J., Flinn I., Jain V., et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study. Blood 99 (2002) 3554-3561
76. Kell W.J., Burnett A.K., Chopra R., et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 102 (2003) 4277-4283
77. Kennedy B., Rawstron A., Carter C., et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 99 (2002) 2245-2247
78. Khorana A., Bunn P., McLaughlin P., et al. A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma. Leuk. Lymphoma 41 (2001) 77-87
79. Kim K.J., Li B., Winer J., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362 (1993) 841-844
80. Koene H.R., Kleijer M., Algra J., et al. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 90 (1997) 1109-1114
81. Köhler G., and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 (1975) 495-497
82. Krackhardt A.M., Witzens M., Harig S., et al. Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood 100 (2002) 2123-2131
83. Kreitman R.J. Recombinant toxins for the treatment of cancer. Curr. Opin. Mol. Ther. 5 (2003) 44-51
84. Kreitman R.J., Wilson W.H., White J.D., et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J. Clin. Oncol. 18 (2000) 1622-1636
85. Kreitman R.J., Wilson W.H., Bergeron K., et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med. 345 (2001) 241-247
86. + memory T cells by opposing cytokines. Science 288 (2000) 675-678
87. Kwon E.D., Foster B.A., Hurwitz A.A., et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc. Natl. Acad. Sci. USA 96 (1999) 15074-15079
88. Larson R.A., Sievers E.L., Stadtmauer E.A., et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (mylotarg) in patients with CD33 positive acute myloid leukemia in first recurrence. Cancer 104 (2005) 1442-1452
89. Laurenti L., Piccioni P., Cattani P., et al. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: Incidence and treatment with oral ganciclovir. Haematologica 89 (2004) 1248-1252
90. Leach D.R., Krummel M.F., and Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271 (1996) 1734-1736
91. Lee C.G., Heijn M., di Tomaso E., et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 60 (2000) 5565-5570
92. Lenardo M.J. Fas and the art of lymphocyte maintenance. J. Exp. Med. 183 (1996) 721-724
93. Lewis G.D., Figari I., Fendly B., et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol. Immunother. 37 (1993) 255-263
94. Linenberger M.L. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: Progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 19 (2005) 176-182
95. Linenberger M.L., Hong T., Flowers D., et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 98 (2001) 988-994
96. Lode H.N., and Reisfeld R.A. Targeted cytokines for cancer immunotherapy. Immunol. Res. 21 (2000) 279-288
97. Lowenberg B., Downing J.R., and Burnett A. Acute myeloid leukemia. N. Engl. J. Med. 341 (1999) 1051-1062
98. Lozanski G., Heerema N.A., Flinn I.W., et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103 (2004) 3278-3281
99. Lundin J., Osterborg A., Brittinger G., et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: A phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J. Clin. Oncol. 16 (1998) 3257-3263
100. Maloney D.G., Liles T.M., Czerwinski D.K., et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84 (1994) 2457-2466
101. Maloney D.G., Grillo-Lopez A.J., Bodkin D.J., et al. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. 15 (1997) 3266-3274
102. Margolin K., Gordon M.S., Holmgren E., et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data. J. Clin. Oncol. 19 (2001) 851-856
103. Marks-Konczalik J., Dubois S., Losi J.M., et al. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc. Natl. Acad. Sci. USA 97 (2000) 11445-11450
104. McLaughlin P., Grillo-Lopez A.J., Link B.K., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16 (1998) 2825-2833
105. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin. Cancer Res. 3 (1997) 2703-2707
106. Mendelsohn J., and Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 19 (2000) 6550-6565
107. Milenic D.E., Brady E.D., and Brechbiel M.W. Antibody-targeted radiation cancer therapy. Nat. Rev. Drug. Discov. 3 (2004) 488-499
108. Miller R.A., Maloney D.G., Warnke R., et al. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N. Engl. J. Med. 306 (1982) 517-522
109. Mir S.S., Richter B.W., and Duckett C.S. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood 96 (2000) 4307-4312
110. Morris J.C., and Waldmann T.A. Advances in interleukin 2 receptor targeted treatment. Ann. Rheum. Dis. 59 Suppl. 1 (2000) i109-i114
111. Mulford D.A., Scheinberg D.A., and Jurcic J.G. The promise of targeted (alpha)-particle therapy. J. Nucl. Med. 46 suppl. 1 (2005) 199S-204S
112. Nadler L.M., Ritz J., Hardy R., et al. A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J. Clin. Invest. 67 (1981) 134-140
113. Naito K., Takeshita A., Shigeno K., et al. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia 14 (2000) 1436-1443
114. Nimmerjahn F., Bruhns P., Horiuchi K., et al. FcgammaRIV: A novel FcR with distinct IgG subclass specificity. Immunity 23 (2005) 41-51
115. Nussenblatt R.B., Fortin E., Schiffman R., et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trial. Proc. Natl. Acad. Sci. USA 96 (1999) 7462-7466
116. 2 antibody fragments for tumor targeting. Protein Eng. Des. Sel. 17 (2004) 315-323
117. Olsen E., Duvic M., Frankel A., et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol. 19 (2001) 376-388
118. Osterborg A., Dyer M.J., Bunjes D., et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J. Clin. Oncol. 15 (1997) 1567-1574
119. Osterborg A., Fassas A.S., Anagnostopoulos A., et al. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br. J. Haematol. 93 (1996) 151-153
120. Pegram M., Hsu S., Lewis G., et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18 (1999) 2241-2251
121. Piro L.D., White C.A., Grillo-Lopez A.J., et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. 10 (1999) 655-661
122. Phan G.Q., Yang J.C., Sherry R.M., et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 100 (2003) 8372-8377
123. Press O.W., Corcoran M., Subbiah K., et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood 98 (2001) 2535-2543
124. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346 (1995) 336-340
125. Press O.W., Shan D., Howell-Clark J., et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res. 56 (1996) 2123-2129
126. Presta L.G., Chen H., O'Connor S.J., et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57 (1997) 4593-4599
127. Queen C., Schneider W.P., Selick H.E., et al. A humanized antibody that binds to the interleukin 2 receptor. Proc. Natl. Acad. Sci. USA 86 (1989) 10029-10033
128. Rai K.R., Freter C.E., Mercier R.J., et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J. Clin. Oncol. 20 (2002) 3891-3897
129. Ravetch J.V., and Lanier L.L. Immune inhibitory receptors. Science 290 (2000) 84-89
130. Rebello P., Cwynarski K., Varughese M., et al. Pharmacokinetics of CAMPATH-1H in BMT patients. Cytotherapy 3 (2001) 261-267
131. Reff M.E., Carner K., Chambers K.S., et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83 (1994) 435-445
132. Riechmann L., Clark M., Waldmann H., et al. Reshaping human antibodies for therapy. Nature 332 (1988) 323-327
133. Riethmuller G., Holz E., Schlimok G., et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial. J. Clin. Oncol. 16 (1998) 1788-1794
134. Robert F., Ezekiel M.P., Spencer S.A., et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J. Clin. Oncol. 19 (2001) 3234-3243
135. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER-2 positive breast cancer. N. Engl. J. Med. 353 (2005) 1673-1684
136. Rosenberg S.A., Yang J.C., Topalian S.L., et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 271 (1994) 907-913
137. Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22 (2004) 531-562
138. Saltz L.B., Meropol N.J., Loehrer Sr. P.J., et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22 (2004) 1201-1208
139. Schwartzentruber D.J., Restifo N.P., Haworth L.R., et al. Cancer regression induced by cytotoxic T-lymphocytes associated antigen 4-blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 100 (2003) 8372-8377
140. Segal D.M., Weiner G.J., and Weiner L.M. Introduction: Bispecific antibodies. J. Immunol. Methods 248 (2001) 1-6
141. Seidman A., Hudis C., Pierri M.K., et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol. 20 (2002) 1215-1221
142. Shevach E.M. Regulatory T cells in autoimmmunity. Annu. Rev. Immunol. 18 (2000) 423-449
143. Shields R.L., Namenuk A.K., Hong K., et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J. Biol. Chem. 276 (2001) 6591-6604
144. Shimizu J., Yamazaki S., and Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: A common basis between tumor immunity and autoimmunity. J. Immunol. 163 (1999) 5211-5218
145. Shin D.M., Donato N.J., Perez-Soler R., et al. Epidermal growth factor receptor targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin. Cancer Res. 7 (2001) 1204-1213
146. Shinkawa T., Nakamura K., Yamane N., et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 278 (2003) 3466-3473
147. Sievers E.L., Appelbaum F.R., Spielberger R.T., et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 93 (1999) 3678-3684
148. Sievers E.L., Larson R.A., Stadtmauer E.A., et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol. 19 (2001) 3244-3254
149. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
150. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344 (2001) 783-792
151. Sliwkowski M.X., Lofgren J.A., Lewis G.D., et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin. Oncol. 26 (1999) 60-70
152. Smith M.R. Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance. Oncogene 22 (2003) 7359-7368
153. Stacy K. Therapeutic MAbs: Saving lives and making billions. The Scientist 19 (2005) 17-19
154. Staerz U.D., Kanagawa O., and Bevan M.J. Hybrid antibodies can target sites for attack by T cells. Nature 314 (1985) 628-631
155. Stashenko P., Nadler L.M., Hardy R., et al. Expression of cell surface markers after human B lymphocyte activation. Proc. Natl. Acad. Sci. USA 78 (1981) 3848-3852
156. Sunada H., Magun B.E., Mendelsohn J., et al. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc. Natl. Acad. Sci. USA 83 (1986) 3825-3829
157. Sutmuller R.P., van Duivenvoorde L.M., van Elsas A., et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194 (2001) 823-832
158. Terabe M., Matsui S., Noben-Trauth N., et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol. 1 (2000) 515-520
159. Thornton A.M., and Shevach E.M. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J. Immunol. 164 (2000) 183-190
160. Treumann A., Lifely M.R., Schneider P., et al. Primary structure of CD52. J. Biol. Chem. 270 (1995) 6088-6099
161. Tsimberidou A., Estey E., Cortes J., et al. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer 97 (2003) 1481-1487
162. Uppenkamp M., Engert A., Diehl V., et al. Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: A multicenter phase I/II study. Ann. Hematol. 81 (2002) 26-32
163. van der Velden V.H., Boeckx N., Jedema I., et al. High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients. Leukemia 18 (2004) 983-988
164. van Der Velden V.H., te Marvelde J.G., Hoogeveen P.G., et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: In vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 97 (2001) 3197-3204
165. Vincenti F., Kirkman R., Light S., et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N. Engl. J. Med. 338 (1998) 161-165
166. Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20 (2002) 719-726
167. von Behring E., and Kitasato S. The mechanism of immunity in animals to diphtheria and tetanus. In: Brock T. (Ed). "Milestones in Microbiology" (1890), Prentice-Hall Int., London 138-140
168. von Mehren M., Adams G.P., and Weiner L.M. Monoclonal antibody therapy for cancer. Annu. Rev. Med. 54 (2003) 343-369
169. Vose J.M., Wahl R.L., Saleh M., et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J. Clin. Oncol. 18 (2000) 1316-1323
170. Wahl R.L. Tositumomab and (131) I therapy in non-Hodgkin's lymphoma. J. Nucl. Med. 46 Suppl. 1 (2005) 165-175
171. Waldmann T.A. Monoclonal antibodies in diagnosis and therapy. Science 252 (1991) 1657-1662
172. Waldmann T. ABCsv of radioisotopes used for radioimmunotherapy: Alpha- and beta-emitters. Leuk. Lymphoma 44 suppl. 3 (2003) S107-S113
173. Waldmann T. Immunotherapy: Past, present and future. Nat. Med. 9 (2003) 269-277
174. Waldmann T.A., and Strober W. Metabolism of immunoglobulins. Prog. Allergy 13 (1969) 1-110
175. Waldmann T.A., White J.D., Goldman C.K., et al. The interleukin-2 receptor: A target for monoclonal antibody treatment of human T-cell lymphotropic I virus induced adult T-cell leukemia. Blood 82 (1993) 1701-1712
176. Waldmann T.A., Dubois S., and Tagaya Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: Implications for immunotherapy. Immunity 14 (2001) 105-110
177. Waldmann T.A., White J.D., Carrasquillo J.C., et al. Radioimmunotherapy of interleukin-2R alpha expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. Blood 86 (1995) 4063-4075
178. Weiden P.L., Breitz H.B., Press O., et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): Initial phase I/II study results. Cancer Biother. Radiopharm. 15 (2000) 15-29
179. Weinblatt M.E., Keystone E.C., Furst D.E., et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis. Rheum. 48 (2003) 35-45
180. Weng W.K., and Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21 (2003) 3940-3947
181. Wing M.G., Moreau T., Greenwood J., et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: Involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J. Clin. Invest. 98 (1996) 2819-2826
182. Winter G., and Milstein C. Man made antibodies. Nature 349 (1991) 293-299
183. Wiseman G.A., Gordon L.I., Multani P.S., et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: A phase II multicenter trial. Blood 99 (2002) 4336-4342
184. Witzig T.E., White C.A., Wiseman G.A., et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 17 (1999) 3793-3803
185. Witzig T.E., Flinn I.W., Gordon L.I., et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J. Clin. Oncol. 20 (2002) 3262-3269
186. Witzig T.E., Gordon L.I., Cabanillas F., et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 20 (2002) 2453-2463
187. Witzig T.E., White C.A., Gordon L.I., et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J. Clin. Oncol. 21 (2003) 1263-1270
188. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349 (2003) 427-434
189. Zalutsky M.R., Garg P.K., and Narula A.S. Labeling monoclonal antibodies with halogen nuclides. Acta Radiol. Suppl. 374 (1990) 141-145
190. Zein N., Sinha A.M., McGahren W.J., et al. Calicheamicin gamma 1I: An antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 240 (1988) 1198-1201
191. Zhang M., Yao Z., Garmestani K., et al. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213. Blood 100 (2002) 208-216
192. Zhang M., Zhang Z., Garmestani K., et al. Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult T-cell leukemia. Cancer Res. 64 (2004) 5825-5829
193. Zhang X., Sun S., Hwang I., et al. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 8 (1998) 591-599
194. Zhao Y., Brown T.L., Kohler H., et al. MTS-conjugated-antiactive caspase 3 antibodies inhibit actinomycin D-induced apoptosis. Apoptosis 8 (2003) 631-637